Free Trial

Kymera Therapeutics (KYMR) Competitors

Kymera Therapeutics logo
$30.17 +0.04 (+0.13%)
Closing price 05/22/2025 04:00 PM Eastern
Extended Trading
$29.30 -0.87 (-2.88%)
As of 05/22/2025 05:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

KYMR vs. ROIV, RVMD, BBIO, BPMC, ELAN, LEGN, TGTX, TLX, VRNA, and LNTH

Should you be buying Kymera Therapeutics stock or one of its competitors? The main competitors of Kymera Therapeutics include Roivant Sciences (ROIV), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Elanco Animal Health (ELAN), Legend Biotech (LEGN), TG Therapeutics (TGTX), Telix Pharmaceuticals Limited American Depositary Shares (TLX), Verona Pharma (VRNA), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry.

Kymera Therapeutics vs.

Roivant Sciences (NASDAQ:ROIV) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership, analyst recommendations and community ranking.

In the previous week, Roivant Sciences had 3 more articles in the media than Kymera Therapeutics. MarketBeat recorded 15 mentions for Roivant Sciences and 12 mentions for Kymera Therapeutics. Roivant Sciences' average media sentiment score of 1.40 beat Kymera Therapeutics' score of 1.24 indicating that Roivant Sciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Roivant Sciences
13 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Kymera Therapeutics
6 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Roivant Sciences has a net margin of -119.54% compared to Kymera Therapeutics' net margin of -191.26%. Roivant Sciences' return on equity of -14.05% beat Kymera Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Roivant Sciences-119.54% -14.05% -12.81%
Kymera Therapeutics -191.26%-24.96%-20.27%

Roivant Sciences has a beta of 1.23, suggesting that its stock price is 23% more volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.18, suggesting that its stock price is 118% more volatile than the S&P 500.

Roivant Sciences presently has a consensus price target of $17.50, suggesting a potential upside of 59.96%. Kymera Therapeutics has a consensus price target of $55.25, suggesting a potential upside of 83.13%. Given Kymera Therapeutics' higher probable upside, analysts plainly believe Kymera Therapeutics is more favorable than Roivant Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Roivant Sciences
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
1 Strong Buy rating(s)
3.00
Kymera Therapeutics
0 Sell rating(s)
4 Hold rating(s)
12 Buy rating(s)
1 Strong Buy rating(s)
2.82

Kymera Therapeutics received 5 more outperform votes than Roivant Sciences when rated by MarketBeat users. However, 78.57% of users gave Roivant Sciences an outperform vote while only 54.55% of users gave Kymera Therapeutics an outperform vote.

CompanyUnderperformOutperform
Roivant SciencesOutperform Votes
55
78.57%
Underperform Votes
15
21.43%
Kymera TherapeuticsOutperform Votes
60
54.55%
Underperform Votes
50
45.45%

64.8% of Roivant Sciences shares are held by institutional investors. 7.9% of Roivant Sciences shares are held by insiders. Comparatively, 16.0% of Kymera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Roivant Sciences has higher revenue and earnings than Kymera Therapeutics. Roivant Sciences is trading at a lower price-to-earnings ratio than Kymera Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Roivant Sciences$122.59M63.68$4.35B-$0.15-72.93
Kymera Therapeutics$58.89M33.36-$146.96M-$3.10-9.73

Summary

Roivant Sciences beats Kymera Therapeutics on 12 of the 18 factors compared between the two stocks.

Get Kymera Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KYMR vs. The Competition

MetricKymera TherapeuticsBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$1.96B$2.93B$5.33B$8.39B
Dividend YieldN/A1.64%5.21%4.11%
P/E Ratio-12.8931.1826.7119.71
Price / Sales33.36398.78386.08120.53
Price / CashN/A168.6838.2534.62
Price / Book4.243.236.774.50
Net Income-$146.96M-$72.35M$3.23B$248.22M
7 Day Performance-0.26%2.49%0.48%-0.78%
1 Month Performance-1.73%2.45%9.10%11.53%
1 Year Performance-11.89%-24.98%18.56%8.99%

Kymera Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KYMR
Kymera Therapeutics
2.738 of 5 stars
$30.17
+0.1%
$55.25
+83.1%
-15.5%$1.96B$58.89M-12.89170Positive News
Analyst Forecast
ROIV
Roivant Sciences
2.1187 of 5 stars
$10.99
+3.3%
$17.50
+59.2%
-3.1%$7.84B$122.59M-73.26860Positive News
Upcoming Earnings
Insider Trade
RVMD
Revolution Medicines
4.3594 of 5 stars
$41.88
+3.6%
$67.17
+60.4%
-2.4%$7.80B$742,000.00-11.67250Positive News
BBIO
BridgeBio Pharma
4.5993 of 5 stars
$35.68
+4.4%
$57.09
+60.0%
+12.6%$6.77B$127.42M-12.52400Insider Trade
BPMC
Blueprint Medicines
2.6022 of 5 stars
$100.31
+3.2%
$126.56
+26.2%
-2.3%$6.48B$562.12M-92.88640Positive News
Insider Trade
ELAN
Elanco Animal Health
3.2246 of 5 stars
$12.82
+7.2%
$15.00
+17.0%
-25.1%$6.36B$4.43B32.049,800Gap Up
LEGN
Legend Biotech
3.5229 of 5 stars
$32.38
+1.9%
$78.82
+143.4%
-31.8%$5.95B$627.24M-34.081,070Positive News
TGTX
TG Therapeutics
3.8069 of 5 stars
$34.99
+4.0%
$40.80
+16.6%
+93.4%$5.56B$386.39M-349.87290Positive News
TLX
Telix Pharmaceuticals Limited American Depositary Shares
N/A$16.25
-5.4%
$22.00
+35.4%
N/A$5.49B$783.21M0.00N/APositive News
VRNA
Verona Pharma
2.6573 of 5 stars
$67.53
+6.6%
$81.50
+20.7%
+476.9%$5.48B$118.54M-35.1730Positive News
Gap Down
LNTH
Lantheus
4.4444 of 5 stars
$79.52
-2.7%
$132.67
+66.8%
-8.1%$5.45B$1.54B13.23700Positive News
High Trading Volume

Related Companies and Tools


This page (NASDAQ:KYMR) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners